| 57.32 -1.1 (-1.88%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 70.8  |
1-year : | 75.68 |
| Resists | First : | 60.62 |
Second : | 64.8 |
| Pivot price | 57.12 |
|||
| Supports | First : | 53.86 | Second : | 44.81 |
| MAs | MA(5) : | 58.65 |
MA(20) : | 57.74 |
| MA(100) : | 69.5 |
MA(250) : | 65.04 |
|
| MACD | MACD : | -1.1 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 62.1 |
D(3) : | 69.9 |
| RSI | RSI(14): 42.5 |
|||
| 52-week | High : | 87.31 | Low : | 47.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HAE ] has closed below upper band by 46.9%. Bollinger Bands are 51.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 58.52 - 58.87 | 58.87 - 59.13 |
| Low: | 55.82 - 56.28 | 56.28 - 56.62 |
| Close: | 56.71 - 57.4 | 57.4 - 57.9 |
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Wed, 08 Apr 2026
Haemonetics (HAE) Is Up 5.7% After FDA Expands VASCADE MVP XL Labeling for Larger EP Sheaths - simplywall.st
Wed, 08 Apr 2026
HAE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Wed, 08 Apr 2026
Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Weakness? - Sahm
Wed, 01 Apr 2026
Haemonetics will post earnings at 6 a.m., then take questions at 8 - Stock Titan
Mon, 30 Mar 2026
FDA expands use of Haemonetics device in atrial fibrillation care - Stock Titan
Wed, 18 Mar 2026
Haemonetics Corporation (HAE) Q3 performance prompts Baird model update, price target falls to $81 - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 46 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 115.2 (%) |
| Shares Short | 1,900 (K) |
| Shares Short P.Month | 2,540 (K) |
| EPS | 3.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.45 |
| Profit Margin | 13.3 % |
| Operating Margin | 21 % |
| Return on Assets (ttm) | 6.4 % |
| Return on Equity (ttm) | 19.2 % |
| Qtrly Rev. Growth | -2.8 % |
| Gross Profit (p.s.) | 17.08 |
| Sales Per Share | 28.4 |
| EBITDA (p.s.) | 7.85 |
| Qtrly Earnings Growth | 28.3 % |
| Operating Cash Flow | 339 (M) |
| Levered Free Cash Flow | 335 (M) |
| PE Ratio | 15.79 |
| PEG Ratio | 0 |
| Price to Book value | 2.94 |
| Price to Sales | 2.01 |
| Price to Cash Flow | 7.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|